Blood cancers

TGA tick for multiple myeloma immunotherapy

Tuesday, 31 Oct 2017


The anti-CD38 immunotherapy daratumumab (Darzalex) has been approved by the TGA for use in multiple myeloma.

The therapy can be used in combination with existing therapies for patients with multiple myeloma who have received at least one therapy, or as a single agent for patients who have received three lines of therapy or who do not respond to standard therapies.

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic